SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Millions, except Share data, unless otherwise specified	9 Months Ended	34 Months Ended				3 Months Ended		9 Months Ended
	Sep. 30, 2012 Entity	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Protalix Bio Therapeutics Incorporation [Member]	Sep. 30, 2012 Pfizer Incorporation [Member]	Sep. 30, 2012 Options and Restricted Shares [Member]	Sep. 30, 2011 Options and Restricted Shares [Member]	Sep. 30, 2012 Options and Restricted Shares [Member]	Sep. 30, 2011 Options and Restricted Shares [Member]	Sep. 30, 2012 Upon Filing of Pediatric Investigation Plan to EMA [Member]	Sep. 30, 2012 Upon each FDA and European Medicine Agency approval [Member]
Significant Accounting Policies [Line Items]
Number of Subsidiaries	2
Pfizer Agreement, upfront payment received		$ 60.0								$ 5.0
Milestone payment triggered											$ 25.0
Pfizer Agreement, future revenues and expense sharing percentage				40.00%	60.00%
Common stock, par value per share	$ 0.001	$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive						7,508,240	7,428,201	7,169,035	7,498,026